Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations

Pain

Volumn 153, Issue 10, 2012, Pages 1997-2008

  Turk, Dennis C ^a   O'Connor, Alec B ^b   Dworkin, Robert H ^b   Chaudhry, Amina ^c   Katz, Nathaniel P ^d   Adams, Edgar H ^e   Brownstein, John S ^f   Comer, Sandra D ^g   Dart, Richard ^h   Dasgupta, Nabarun ⁱ   Denisco, Richard A ^j   Klein, Michael ^k   Leiderman, Deborah B ^l   Lubran, Robert ^c   Rappaport, Bob A ^k   Zacny, James P ^m   Ahdieh, Harry ⁿ   Burke, Laurie B ^k   Cowan, Penney ^o   Jacobs, Petra ^j   Malamut, Richard ^p   Markman, John ^b   Michna, Edward ^q   Palmer, Pamela ^r   Peirce Sandner, Sarah ^b   Potter, Jennifer S ^s   Raja, Srinivasa N ^c   Rauschkolb, Christine ^t   Roland, Carl L ^u   Webster, Lynn R ^v   Weiss, Roger D ^f   Wolf, Kerry ^w   more..

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d TUFTS UNIVERSITY   (United States)

^e Covance ^*  (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^k CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^l CNS Drug Consulting   (United States)

^m UNIVERSITY OF CHICAGO   (United States)

ⁿ Endo Pharmaceuticals   (United States)

^o American Chronic Pain Association   (United States)

^p ASTRAZENECA   (United Kingdom)

^q BRIGHAM AND WOMEN S HOSPITAL   (United States)

^r AcelRx Pharmaceuticals   (United States)

^s UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^t JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^u PFIZER INC   (United States)

^v Clinical Research and Pain Clinic   (United States)

^w NAMA Recovery   (United States)

more..

Author keywords

Abuse; Abuse deterrent formulation; Abuse liability; Opioids; Risk of abuse; Study design

Indexed keywords

ANALGESIC AGENT; OPIATE; RECREATIONAL DRUG;

CHRONIC PAIN; CLINICAL ASSESSMENT; CLINICAL STUDY; CONSENSUS DEVELOPMENT; DATA BASE; DRUG ABUSE; DRUG FORMULATION; DRUG MARKETING; DRUG MISUSE; DRUG SURVEILLANCE PROGRAM; HEALTH CARE UTILIZATION; HUMAN; HUMAN ABUSE LIABILITY ASSESSMENT; INFORMATION PROCESSING; METHODOLOGY; OPIATE ADDICTION; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN;

ANALGESICS, OPIOID; DRUG DISCOVERY; HUMANS; OPIOID-RELATED DISORDERS; PAIN; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; UNITED STATES;

EID: 84866353244     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2012.05.029     Document Type: Review

References (77)

1. E.H. Adams, S. Breiner, T.J. Cicero, A. Geller, J.A. Inciardi, S.H. Schnoll, E.C. Senay, and G.E. Woody A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain J Pain Symptom Manage 31 2006 465 476
2. H. Alho, D. Sinclair, E. Vuori, and A. Holopainen Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users Drug Alcohol Depend 88 2007 75 78
3. P.G. Arbogast, and W.A. Ray Use of disease risk scores in pharmacoepidemiologic studies Stat Methods Med Res 18 2009 67 80
4. S.E. Back, R.A. Payne, A.E. Waldrop, A. Smith, S. Reeves, and K.T. Brady Prescription opioid aberrant behaviors: a pilot study of sex differences Clin J Pain 25 2009 477 484
5. J.E. Bailey, E. Campagna, and R.C. Dart System Poison Center Investigators. The underrecognized toll of prescription opioid abuse on young children Ann Emerg Med 53 2009 419 424
6. C.M. Bieber, K. Fernandez, D. Borsook, M.J. Brennan, S.F. Butler, R.N. Jamison, E. Osgood, J. Sharpe-Potter, H.N. Thomson, R.D. Weiss, and N.P. Katz Retrospective accounts of initial subjective effects of opioids in patients treated for pain who do or do not develop opioid addiction: a pilot case-control study Exp Clin Psychopharmacol 16 2008 429 434
7. P. Braitstein, K. Li, M. Tyndall, P. Spittal, M.V. O'Shaughnessy, A. Schilder, C. Johnston, R.S. Hogg, and M.T. Schechter Sexual violence among a cohort of injection drug users Soc Sci Med 57 2003 561 569
8. C.L. Breen, L.J. Degenhardt, R.B. Bruno, A.D. Roxburgh, and R. Jenkinson The effects of restricting publicly subsidised temazepam capsules on benzodiazepine use among injecting drug users in Australia Med J Aust 181 2004 300 304
9. R.D. Bruce, S. Govindasamy, L. Sylla, A. Kamarulzaman, and F.L. Altice Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market Am J Drug Alcohol Abuse 35 2009 68 72
10. S.H. Budman, J.M. Grimes Serrano, and S.F. Butler Can abuse deterrent formulations make a difference? Expectation and speculation Harm Reduct J 6 2009 8
11. S.F. Butler, C. Benoit, S.H. Budman, K.C. Fernandez, C. McCormick, S.W. Venuti, and N. Katz Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers Harm Reduct J 3 2006 5
12. S.F. Butler, S.H. Budman, A. Licari, T.A. Cassidy, K. Lioy, J. Dickenson, J.S. Brownstein, J.C. Benneyan, T.C. Green, and N. Katz National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse Pharmacoepidemiol Drug Saf 17 2008 1142 1154
13. S.F. Butler, S.H. Budman, K.C. Fernandez, B. Houle, C. Benoit, N. Katz, and R.N. Jamison Development and validation of the Current Opioid Misuse Measure PAIN® 130 2007 144 156
14. S.F. Butler, K. Fernandez, C. Benoit, S.H. Budman, and R.N. Jamison Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R) J Pain 9 2008 360 372
15. M.P. Carrieri, J.P. Moatti, D. Vlahov, Y. Obadia, C. Reynaud-Maurupt, and M. Chesney Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group J Epidemiol Community Health 1999 2000 4 8
16. M.P. Carrieri, V. Villes, F. Raffi, C. Protopopescu, M. Preau, D. Salmon, A. Taieb, J.M. Lang, R. Verdon, G. Chene, and B. Spire Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8) Int J Drug Policy 18 2007 288 295
17. L.P. Carter, and R.R. Griffiths Principles of laboratory assessment of drug abuse liability and implications for clinical development Drug Alcohol Depend 105 2009 S14 S25
18. C.R. Chapman, D.L. Lipschitz, M.S. Angst, R. Chou, R.C. Denisco, G.W. Donaldson, P.G. Fine, K.M. Foley, R.M. Gallagher, A.M. Gilson, J.D. Haddox, S.D. Horn, C.E. Inturrisi, S.S. Jick, A.G. Lipman, J.D. Loeser, M. Noble, L. Porter, M.C. Rowbotham, K.M. Schoelles, D.C. Turk, E. Volinn, M.R. Von Korff, L.R. Webster, and C.M. Weisner Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base J Pain 11 2010 807 829
19. R. Chou, G.J. Fanciullo, P.G. Fine, C. Miaskowski, S.D. Passik, and R.K. Portenoy Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline J Pain 10 2009 131 146
20. T.J. Cicero, J.A. Inciardi, and A. Muñoz Trends in abuse of Oxycontin and other opioid analgesics in the United States:2002-2004 J Pain 6 2005 662 672
21. S.D. Comer, J.B. Ashworth, R.W. Foltin, C.E. Johanson, J.P. Zacny, and S.L. Walsh The role of human drug self-administration procedures in the development of medications Drug Alcohol Depend 96 2008 1 15
22. Committee on Advancing Pain Research, Care, and Education, Institute of Medicine Relieving pain in America: a blueprint for transforming prevention, care, education, and research 2011 National Academies Press Washington, DC
23. W.M. Compton, and N.D. Volkow Major increases in opioid analgesic abuse in the United States: concerns and strategies Drug Alcohol Depend 81 2006 103 107
24. E.J. Cone, R.V. Fant, J.M. Rohay, Y.H. Caplan, M. Ballina, R.F. Reder, D. Spyker, and J.D. Haddox Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases J Anal Toxicol 27 2003 57 67
25. R.C. Dart Monitoring risk: post marketing surveillance and signal detection Drug Alcohol Depend 105S 2009 S26 S32
26. N. Dasgupta, K.D. Mandl, and J.S. Brownstein Breaking the news or fueling the epidemic? Temporal association between news media report volume and opioid-related mortality PLoS One 4 2009 e7758
27. L. Degenhardt, A. Roxburgh, I. van Beek, W.D. Hall, M.K. Robinson, J. Ross, and A. Mant The effects of the market withdrawal of temazepam gel capsules on benzodiazepine injecting in Sydney, Australia Drug Alcohol Rev 27 2008 145 151
28. R.A. Denisco, R.K. Chandler, and W.M. Compton Addressing the intersecting problems of opioid misuse and chronic pain treatment Exp Clin Psychopharmacol 16 2008 417 428
29. M. Dobbin, F.R. Martyres, D. Clode, and F.E. Champion De Crespigny Association of benzodiazepine injection with the prescription of temazepam capsules Drug Alcohol Rev 22 2003 153 157
30. T.J. Dodd, R.N. Scott, K.R. Woodburn, and J.J. Going Limb ischaemia after intra-arterial injection of Temazepam gel: histology of nine cases J Clin Pathol 47 1994 512 514
31. R.H. Dworkin, D.C. Turk, J.T. Farrar, J.A. Haythornthwaite, M.P. Jensen, N.P. Katz, R.D. Kerns, G. Stucki, R.R. Allen, N. Bellamy, D.B. Carr, J. Chandler, P. Cowan, R. Dionne, B.S. Galer, S. Hertz, A.R. Jadad, L.D. Kramer, D.C. Manning, S. Martin, C.G. McCormick, M.P. McDermott, P. McGrath, S. Quessy, B.A. Rappaport, W. Robbins, J.P. Robinson, M. Rothman, M.A. Royal, L. Simon, J.W. Stauffer, W. Stein, J. Tollett, and J. Wernicke IMMPACT. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations PAIN® 113 2005 9 19
32. R.H. Dworkin, D.C. Turk, S. Peirce-Sandner, R. Baron, N. Bellamy, L.B. Burke, A. Chappell, K. Chartier, C.S. Cleeland, A. Costello, P. Cowan, R. Dimitrova, S. Ellenberg, J.T. Farrar, J.A. French, I. Gilron, S. Hertz, A.R. Jadad, G.W. Jay, J. Kalliomäki, N.P. Katz, R.D. Kerns, D.C. Manning, M.P. McDermott, P. McGrath, A. Narayana, L. Porter, S. Quessy, B.A. Rappaport, C. Rauschkolb, B. Reeve, T. Rhodes, C. Sampaio, D.M. Simpson, J.W. Stauffer, G. Stucki, J. Tobias, R.E. White, and J. Witter Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations PAIN® 149 2010 177 193
33. D. Faries, H. Ascher-Svanum, and M. Belger Analysis of treatment effectiveness in longitudinal observational data J Biopharm Stat 17 2007 809 826
34. D.A. Fishbain, B. Cole, J. Lewis, H.L. Rosomoff, and R.S. Rosomoff What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review Pain Med 9 2008 444 459
35. D.A. Fishbain, H.L. Rosomoff, and R.S. Rosomoff Drug abuse, dependence, and addiction in chronic pain patients Clin J Pain 8 1992 77 85
36. S. Greenland, and B. Brumback An overview of relations among causal modelling methods Int J Epidemiol 31 2002 1030 1037
37. R.R. Griffiths, G.E. Bigelow, and N.A. Ator Principles of initial experimental drug abuse liability assessment in humans Drug Alcohol Depend 70 2003 S41 S54
38. R.H. Groenwold, E. Hak, and A.W. Hoes Quantitative assessment of unobserved confounding is mandatory in nonrandomized intervention studies J Clin Epidemiol 62 2009 22 28
39. A.J. Hall, J.E. Logan, R.L. Toblin, J.A. Kaplan, J.C. Kraner, D. Bixler, A.E. Crosby, and L.J. Paulozzi Patterns of abuse among unintentional pharmaceutical overdose fatalities JAMA 300 2008 2613 2620
40. J.M. Haro, S. Kontodimas, M.A. Negrin, M. Ratcliffe, D. Suarez, and F. Windmeijer Methodological aspects in the assessment of treatment effects in observational health outcomes studies Appl Health Econ Health Policy 5 2006 11 25
41. T.J. Ives, P.R. Chelminski, C.A. Hammett-Stabler, R.M. Malone, J.S. Perhac, N.M. Potisek, B.B. Shilliday, D.A. DeWalt, and M.P. Pignone Predictors of opioid misuse in patients with chronic pain: a prospective cohort study BMC Health Serv Res 6 2006 46
42. R.N. Jamison, J. Kauffman, and N.P. Katz Characteristics of methadone maintenance patients with chronic pain J Pain Symptom Manage 19 2000 53 62
43. M.M. Joffe, and P.R. Rosenbaum Invited commentary: propensity scores Am J Epidemiol 150 1999 327 333
44. N. Katz Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 10 2008 11 18
45. N.P. Katz, E.H. Adams, H. Chilcoat, R.D. Colluci, S.D. Comer, P. Goliber, C. Grudzinskas, D. Jasinski, S.D. Lande, S.D. Passik, S.H. Schnoll, E. Sellers, D. Travers, and R. Weiss Challenges in the development of prescription opioid abuse-deterrent formulations Clin J Pain 23 2007 648 660
46. N.P. Katz, D.C. Buse, S.H. Budman, S. Wing Venuti, K.C. Fernandez, C. Benoit, R. Bianchi, D. Cooper, D.R. Jasinski, D.E. Smith, and S.F. Butler Development and preliminary experience with an ease of extractability rating system for prescription opioids Drug Dev Pharm 32 2006 727 746
47. N. Katz, L. Panas, M. Kim, A.D. Audet, A. Bilansky, J. Eadie, P. Kreiner, F.C. Paillard, C. Thomas, and G. Carrow Usefulness of prescription monitoring programs for surveillance - analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006 Pharmacoepidemiol Drug Saf 19 2010 115 123
48. N.P. Katz, S. Sherburne, M. Beach, R.J. Rose, J. Vielguth, J. Bradley, and G.J. Fanciullo Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy Anesth Analg 97 2003 1097 1102
49. O.H. Klungel, E.P. Martens, B.M. Psaty, D.E. Grobbee, S.D. Sullivan, B.H. Stricker, H.G. Leufkens, and A. de Boer Methods to assess intended effects of drug treatment in observational studies are reviewed J Clin Epidemiol 57 2004 1223 1231
50. Lanier D, Ko S. Screening in primary care settings for illicit drug use: assessment of screening instruments - a supplemental evidence update for the US Preventive Services Task Force. AHRQ, Publication No. 08-05108-EF-2. January 2008.
51. L. Manchikanti, and A. Singh Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids Pain Physician 11 2008 S63 S88
52. S.S. Martins, K.M. Keyes, C.L. Storr, H. Zhu, and H.D. Chilcoat Pathways between nonmedical opioid use/dependence and psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions Drug Alcohol Depend 103 2009 16 24
53. S.S. Martins, C.L. Storr, H. Zhu, and H.D. Chilcoat Correlates of extramedical use of OxyContin versus other analgesic opioids among the US general population Drug Alcohol Depend 99 2009 58 67
54. S.E. McCabe, J.A. Cranford, M. Morales, and A. Young Simultaneous and concurrent polydrug use of alcohol and prescription drugs: prevalence, correlates, and consequences J Stud Alcohol 67 2006 529 537
55. S. McColl, and E.M. Sellers Research design strategies to evaluate the impact of formulations on abuse liability Drug Alcohol Depend 83S 2006 S52 S62
56. J.D. Morris, E.T. Golub, S.H. Mehta, L.P. Jacobson, and S.J. Gange Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts AIDS Res Ther 4 2007 12
57. M. Préau, C. Protopopescu, B. Spire, A. Sobel, P. Dellamonica, J.P. Moatti, and M.P. Carrieri MANIF-2000 Study Group. Health related quality of life among both current and former injection drug users who are HIV-infected Drug Alcohol Depend 86 2007 175 182
58. S.M. Ruben, and C.L. Morrison Temazepam misuse in a group of injecting drug users Br J Addict 87 1992 1387 1392
59. R.N. Scott, J. Going, K.R. Woodburn, D.G. Gilmour, D.B. Reid, D.P. Leiberman, B. Maraj, and J.G. Pollock Intra-arterial temazepam BMJ 304 1992 1630
60. E.M. Sellers, R. Schuller, M.K. Romach, and G.L. Horbay Relative abuse potential of opioid formulations in Canada: a structured field study J Opioid Manage 2 2006 219 227
61. J. Strang, N. Seivewright, and M. Farrell Intravenous and other novel abuses of benzodiazepines: the opening of Pandora's box? Br J Addict 87 1992 1373 1375
62. T. Stürmer, R.J. Glynn, K.J. Rothman, J. Avorn, and S. Schneeweiss Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information Med Care 45 2007 S158 S165
63. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Vol. 1. Summary of National Findings. Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 11-46585. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2011.
64. Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS). Highlights-2007. National Admissions to Substance Abuse Treatment Services. Office of Applied Studies, DASIS Series S-45, DHHS Publication No. SMA 09-4360. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2009. Available at: < http://www.dasis.samhsa.gov/ teds07/tedshigh2k7.pdf > [accessed 29.8.2011.
65. M.D. Sullivan, M.J. Edlund, M.-Y. Fan, and A. Devries Brennen Braden J, Martin BC. Risk for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and Medicaid insurance plans: the TROUP study PAIN® 15 2010 332 339
66. D.C. Turk, R.H. Dworkin, R.R. Allen, N. Bellamy, N. Brandenburg, D.B. Carr, C. Cleeland, R. Dionne, J.T. Farrar, B.S. Galer, D.J. Hewitt, A.R. Jadad, N.P. Katz, L.D. Kramer, D.C. Manning, C.G. McCormick, M.P. McDermott, P. McGrath, S. Quessy, B.A. Rappaport, J.P. Robinson, M.A. Royal, L. Simon, J.W. Stauffer, W. Stein, J. Tollett, and J. Witter Core outcome domains for chronic pain clinical trials: IMMPACT recommendations PAIN® 106 2003 337 345
67. D.C. Turk, R.H. Dworkin, M.P. McDermott, N. Bellamy, L.B. Burke, J.M. Chandler, C.S. Cleeland, P. Cowan, R. Dimitrova, J.T. Farrar, S. Hertz, J.F. Heyse, S. Iyengar, J.R. Jadad, G.W. Jay, J.A. Jermano, N.P. Katz, D.C. Manning, S. Martin, M.B. Max, P. McGrath, H.J. McQuay, S. Quessy, B.A. Rappaport, D.A. Revicki, M. Rothman, J.W. Stauffer, O. Svensson, R.E. White, and J. Witter Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations PAIN® 139 2008 485 493
68. D.C. Turk, K.S. Swanson, and R.J. Gatchel Predicting opioid misuse by chronic pain patients: asymptomatic review and literature synthesis Clin J Pain 24 2008 497 508
69. United States Food and Drug Administration, Center for Drug Evaluation and Research. Transcript of the Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and Drug Safety & Risk Management Advisory Committee, May 6, 2008. Available at: < http://www.fda.gov/ohrms/dockets/ac/ 08/transcripts/2008-4356t2-part2.pdf >, p. 44-45. [accessed 5.2.2011.
70. D. Vlahov, J.C. Anthony, A. Munoz, J. Margolick, K.E. Nelson, D.D. Celentano, L. Soloman, and B.F. Polk The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants NIDA Res Monogr 109 1991 75 100
71. N.D. Volkow, T.A. McLellan, J.H. Cotto, M. Marithanom, and S.R.B. Weiss Characteristics of opioid prescriptions in 2009 JAMA 305 2011 1299 1300
72. A.D. Wasan, S.F. Butler, S.H. Budman, C. Beniot, K. Fernandez, and R.N. Jamison Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain Clin J Pain 23 2007 307 315
73. M.F. Weaver, and S.H. Schnoll Opioid treatment of chronic pain in patients with addiction J Pain Palliat Care Pharmacother 16 2002 5 26
74. A.G. White, H.G. Birnbaum, M. Schiller, J. Tang, and N.P. Katz Analytic models to identify patients at risk for prescription opioid abuse Am J Manage Care 15 2009 897 906
75. E. Wood, T. Kerr, B.D. Marshall, K. Li, R. Zhang, R.S. Hogg, and P.R. Harrigan Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study BMJ 338 2009 b1649
76. C. Wright 4th, E.D. Kramer, M.A. Zalman, M.Y. Smith, and J.D. Haddox Risk identification, risk assessment, and risk management of abusable drug formulations Drug Alcohol Depend 83 2006 S68 S76
77. L.T. Wu, C.L. Ringwalt, P. Mannelli, and A.A. Patkar Prescription pain reliever abuse and dependence among adolescents: a nationally representative study J Am Acad Child Adolesc Psychiatry 47 2008 1020 1029